# Debate Matchup Judgment Report

**Gemini 3.8 Flash (high)** vs **GLM-5.3 (high)**

- Paired result: **GLM-5.3 (high)**
- Mean entertainment: `7.83 / 10`
- Judge decisions: `6` across two side-swapped debates

**Motion:** Health systems should permit and reimburse AI-assisted clinical documentation and triage only if models meet publicly reported accuracy and bias benchmarks.

## Debates and evidence

- [Debate A transcript](../../../transcripts/prop_0624__gemini-3.8-flash-high__glm-5-3-high__s0__tpl_placement_active_20260813a.md): PRO = **Gemini 3.8 Flash (high)**, CON = **GLM-5.3 (high)**
- [Debate B transcript](../../../transcripts/prop_0624__glm-5-3-high__gemini-3.8-flash-high__s1__tpl_placement_active_20260813a.md): PRO = **GLM-5.3 (high)**, CON = **Gemini 3.8 Flash (high)**
- [Public judge decision table](../../../judgments/judge_results__judge_blend_glm53_coverage_20260904a.csv)

## Debate A

- Transcript: [read the full debate](../../../transcripts/prop_0624__gemini-3.8-flash-high__glm-5-3-high__s0__tpl_placement_active_20260813a.md)
- Roles: PRO = **Gemini 3.8 Flash (high)**, CON = **GLM-5.3 (high)**
- Judged result: Unanimous `3-0` for **GLM-5.3 (high)**.
- Entertainment scores: `7`, `8`, `8`
- Mean signed raw margin (PRO+): `-1.93`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Claude Sonnet 5 (high) | A = Gemini 3.8 Flash (high) (PRO); B = GLM-5.3 (high) (CON) | GLM-5.3 (high) | -1.8 | -1.75 | 7.0 |
| Kimi K2.6 | A = Gemini 3.8 Flash (high) (PRO); B = GLM-5.3 (high) (CON) | GLM-5.3 (high) | -1.5 | -1.70 | 8.0 |
| Qwen 3.7 Max | A = Gemini 3.8 Flash (high) (PRO); B = GLM-5.3 (high) (CON) | GLM-5.3 (high) | -2.5 | -2.12 | 8.0 |

### Judge Notes

- **Claude Sonnet 5 (high)** (A = Gemini 3.8 Flash (high) (PRO); B = GLM-5.3 (high) (CON)): The debate hinged on the word "only" in the motion, and B consistently exploited that exclusivity while A never fully resolved it. B's core scenario—a tool that passes regulatory review, local validation, and phased deployment but lacks a publicly posted score—was pressed repeatedly (B1, B2, PQ2, B4, closing) and A's answer ("publishing is trivially easy," secrecy implies hiding disparate error rates) was asserted rather than argued, and B correctly flagged this as an unsupported inference used to justify exclusion. B also landed a clean structural point that A's own answer to staleness (reimbursement "pauses" on stale scores) conceded the gate is unstable and creates coverage churn, which A never adequately rebutted afterward. A's drug/formulary analogy, central to the opening, was directly undercut by B's observation that drug approval doesn't work via public benchmark scorecards but via confidential regulatory review plus surveillance—a comparison A did not fully answer, largely repeating the analogy rather than defending it against B's rebuttal. A's case remained strong on the values side (transparency, equity, distrust of vendor claims) but weaker on the mechanics of the "only" gate, which is the precise textual crux. B's pressure questions were sharper and more clearly exposed a live tension (Q2 on exclusion of validated-but-unpublished tools) than A's questions, which B answered fairly directly with A1/A2 labels. Overall B did more work narrowing the clash to the decisive exclusivity problem and sustained pressure on it through to the close, while A's rebuttals recycled the same equity/transparency framing without closing the structural gap B kept reopening.
  Most decisive rebuttal noted: B's repeated pressure (opening B1.6, Rebuttal1 B2.3, PQ B3.2, Rebuttal2 B4.5, closing B5.1) on the hypothetical of a tool that clears regulatory review, local validation, and phased deployment but lacks a public score—paired with A's concession-like answer that reimbursement would "pause" for stale scores—was the most decisive exchange, since it exposed the motion's "only" clause as producing exclusion and instability that A never neutralized.
- **Kimi K2.6** (A = Gemini 3.8 Flash (high) (PRO); B = GLM-5.3 (high) (CON)): CON successfully undermined PRO's core analogy to drug regulation by showing that existing medical governance relies on confidential regulatory review rather than public scorecards. PRO struggled to defend the exclusivity of "only if" against CON's sustained pressure: the drug analogy backfired, the "trivially easy" publication claim ignored infrastructure burdens pressed by CON, and PRO never fully answered why a tool passing substantive local and regulatory review should be denied reimbursement solely for lacking a public benchmark. CON's "theater of a number" framing crystallized the clash effectively, while PRO's equity argument, though live, remained more speculative against CON's concrete harms of exclusion and stale snapshots.
  Most decisive rebuttal noted: CON's turn of PRO's drug analogy in Rebuttal 1 (B2.1-B2.2), demonstrating that pharmaceuticals reach patients through confidential regulatory review and post-market surveillance—not public benchmarks—thereby showing PRO's proposed system was actually an anomaly in medical governance and supporting CON's alternative framework.
- **Qwen 3.7 Max** (A = Gemini 3.8 Flash (high) (PRO); B = GLM-5.3 (high) (CON)): Side B delivered exceptionally sharp rebuttals, decisively turning Side A's drug analogy and safety-net hospital arguments against them. By pointing out that drugs are approved via confidential regulatory review rather than public scorecards, and that rural hospitals rely on regulators rather than conducting their own audits, Side B dismantled Side A's core practical claims. Side B also effectively exploited Side A's concession that reimbursement would "pause" during model updates, proving the "only if" gate creates harmful churn. Side B's framing of "theater of a number" versus substantive oversight was highly persuasive and grounded in the reality of medical regulation.
  Most decisive rebuttal noted: Side B's dismantling of Side A's drug analogy in Rebuttal 1, pointing out that drug formulary access is gated by confidential regulatory review, not public benchmark scorecards, which perfectly mirrored Side B's preferred alternative and neutralized Side A's strongest rhetorical comparison.

## Debate B

- Transcript: [read the full debate](../../../transcripts/prop_0624__glm-5-3-high__gemini-3.8-flash-high__s1__tpl_placement_active_20260813a.md)
- Roles: PRO = **GLM-5.3 (high)**, CON = **Gemini 3.8 Flash (high)**
- Judged result: Unanimous `3-0` for **GLM-5.3 (high)**.
- Entertainment scores: `8`, `8`, `8`
- Mean signed raw margin (PRO+): `+1.80`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Claude Sonnet 5 (high) | A = GLM-5.3 (high) (PRO); B = Gemini 3.8 Flash (high) (CON) | GLM-5.3 (high) | +1.8 | +1.75 | 8.0 |
| Kimi K2.6 | A = GLM-5.3 (high) (PRO); B = Gemini 3.8 Flash (high) (CON) | GLM-5.3 (high) | +1.6 | +1.81 | 8.0 |
| Qwen 3.7 Max | A = GLM-5.3 (high) (PRO); B = Gemini 3.8 Flash (high) (CON) | GLM-5.3 (high) | +2.0 | +1.70 | 8.0 |

### Judge Notes

- **Claude Sonnet 5 (high)** (A = GLM-5.3 (high) (PRO); B = Gemini 3.8 Flash (high) (CON)): Both sides built coherent, well-grounded cases without fabricated evidence, and the pressure questions round was used properly by both. The decisive turn was PRO's move in Rebuttal 1/2: it converted CON's "human-in-the-loop" and "institutional governance" defenses into concessions that validation, audits, and subgroup-sensitive measurement are necessary, then reframed the entire dispute as "the same apparatus, but private vs. public" — a framing CON never squarely dismantled. CON's strongest counter-pressure (that the motion's "permit... only if" language forces an immediate freeze/ban on all current tools since no such public benchmarks yet exist) was a real hit, but PRO's answer ("staged transition," benchmarks built from existing data) at least partially defused it, while CON's own answer to PRO's Q1 (how would an outside patient/clinician ever learn a model failed their subgroup under pure local audits) was answered with generic appeals to malpractice/licensing incentives rather than addressing the actual discoverability gap. PRO's closing crystallized this asymmetry cleanly (lawsuits arrive "after the harm, one at a time"), while CON's closing mostly restated earlier framing (blunt leaderboard, automation bias, bedside safety) without directly rebutting the transparency/discovery argument. This makes PRO's path to victory more resolved and CON's more exposed, yielding a clear but not overwhelming win for PRO.
  Most decisive rebuttal noted: PRO's [A4.3]-[A4.4] turn — arguing CON's own proposed regime (local validation, continuous audits) requires the identical measurement apparatus PRO demands, differing only in whether results are public — was the most decisive exchange, since CON's subsequent answers and closing never directly neutralized the core claim that private-only validation hides subgroup failures from other institutions and patients.
- **Kimi K2.6** (A = GLM-5.3 (high) (PRO); B = Gemini 3.8 Flash (high) (CON)): PRO wins by collapsing the debate to a single, decisive question: if both sides agree that AI documentation and triage require validation, audits, and subgroup analysis, then the only live dispute is whether those results should be public. CON repeatedly defended local institutional governance and internal audits, but never gave a satisfying reason why the same measurement burden should be conducted in secret. PRO's pressure questions exposed this burden directly—asking what prevents hospitals from grading their own homework and why unbenchmarked vendor marketing would reduce automation bias rather than increase it. CON's answers (malpractice liability, hospital protocols treating unverified tools as drafts) assumed safeguards that exist precisely because institutions treat these tools skeptically, while PRO showed that private validation leaves subgroup failures invisible to the next hospital and the affected patients. PRO's staged-transition answer to the "immediate ban" objection was reasonable given the normative "should" framing, and the weighing in the second rebuttal—paperwork delay versus patients who never make it onto the triage list—crystallized the stakes cleanly. CON's local-adaptation and Goodhart arguments retained some force, but never overcame the core asymmetry that PRO established: public benchmarks are local validation with the lights on, and CON never justified keeping the lights off.
  Most decisive rebuttal noted: PRO's reframing in the second rebuttal and closing that CON's alternative requires the exact same measurement costs—local validation, continuous audits, adverse-event tracking—except run in private, so the only thing CON actually opposes is disclosure. This neutralized much of CON's regulatory-burden argument and flipped the burden onto CON to explain why hidden validation protects patients better than transparent validation.
- **Qwen 3.7 Max** (A = GLM-5.3 (high) (PRO); B = Gemini 3.8 Flash (high) (CON)): Side A won by successfully crystallizing the debate in the later rounds around the distinction between public and private reporting. While Side B made strong arguments about the need for local fine-tuning and the dangers of static benchmarks, Side A effectively neutralized these by arguing that local-only validation hides cross-population subgroup failures and allows hospitals to grade their own homework. Side A's framing that their proposal is simply the same validation regime with the lights on was highly persuasive and difficult for Side B to overcome. Side A also handled the pressure questions more effectively, minimizing the delay impact of benchmarking patches and turning the burnout impact by pointing out that Side B's alternative requires the same validation costs.
  Most decisive rebuttal noted: Side A's response to the local patch pressure question and subsequent rebuttal, where they conceded that patches must be tested but reframed it as a mere compute job rather than a multi-year trial, while highlighting that unmeasured patches risk silently degrading performance for other subgroups. This effectively blunted Side B's strongest practical objection regarding agility.

## Technical metadata

- Evaluation scope: `judge_judge_blend_glm53_coverage_20260904a__debate_all_templates`
- Topic ID: `prop_0624`
- Side-swap group ID: `prop_0624__gemini-3.8-flash-high__glm-5-3-high__tpl_placement_active_20260813a`
- Raw paired winner: **GLM-5.3 (high)**
- Mean normalized margin for Gemini 3.8 Flash (high): `-1.81`
- Complete side swap: `yes`
- Included in ratings: `yes`
